Skip to main content
Journal cover image

Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension

Publication ,  Conference
Crombez, E; Kishnani, P; Turkia, HB; Gonzalez, D; Zimran, A; Kabra, M; Lukina, E; Giraldo, P; Kisinovsky, I; Bavdekar, A; Dridi, M-FB; Gupta, N
Published in: Molecular Genetics and Metabolism
February 2012

Duke Scholars

Published In

Molecular Genetics and Metabolism

DOI

ISSN

1096-7192

Publication Date

February 2012

Volume

105

Issue

2

Start / End Page

S25 / S26

Publisher

Elsevier BV

Related Subject Headings

  • Genetics & Heredity
  • 3202 Clinical sciences
  • 3105 Genetics
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crombez, E., Kishnani, P., Turkia, H. B., Gonzalez, D., Zimran, A., Kabra, M., … Gupta, N. (2012). Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. In Molecular Genetics and Metabolism (Vol. 105, pp. S25–S26). Elsevier BV. https://doi.org/10.1016/j.ymgme.2011.11.044
Crombez, Eric, Priya Kishnani, Hadhami Ben Turkia, Derlis Gonzalez, Ari Zimran, Madhulika Kabra, Elena Lukina, et al. “Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension.” In Molecular Genetics and Metabolism, 105:S25–26. Elsevier BV, 2012. https://doi.org/10.1016/j.ymgme.2011.11.044.
Crombez E, Kishnani P, Turkia HB, Gonzalez D, Zimran A, Kabra M, et al. Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. In: Molecular Genetics and Metabolism. Elsevier BV; 2012. p. S25–6.
Crombez, Eric, et al. “Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension.” Molecular Genetics and Metabolism, vol. 105, no. 2, Elsevier BV, 2012, pp. S25–26. Crossref, doi:10.1016/j.ymgme.2011.11.044.
Crombez E, Kishnani P, Turkia HB, Gonzalez D, Zimran A, Kabra M, Lukina E, Giraldo P, Kisinovsky I, Bavdekar A, Dridi M-FB, Gupta N. Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension. Molecular Genetics and Metabolism. Elsevier BV; 2012. p. S25–S26.
Journal cover image

Published In

Molecular Genetics and Metabolism

DOI

ISSN

1096-7192

Publication Date

February 2012

Volume

105

Issue

2

Start / End Page

S25 / S26

Publisher

Elsevier BV

Related Subject Headings

  • Genetics & Heredity
  • 3202 Clinical sciences
  • 3105 Genetics
  • 1103 Clinical Sciences